

## AETHER THERAPEUTICS

Breaking the Chains of Opioid Addiction

### FUNDING TO DATE

**\$7 Million**

\$5M in grants

### CURRENT RAISE

**\$10M Convertible Note**

\$6M committed · Lead investor secured

### STAGE

Phase 1/2 Clinical Studies

### VALUE INFLECTION

**Human Proof of Principle**

COPT patients · Within 2.5 years

### EXIT TIMELINE

**Potential exit < 3 years**

10X+ return potential

### CONTACT

**Aaron Schuchart, MBA**

President & CEO

[aaron@aetherthx.com](mailto:aaron@aetherthx.com)

# Aether Therapeutics

ADDRESSING THE GLOBAL OPIOID CRISIS BY TARGETING THE MOLECULAR CAUSE OF DEPENDENCE

## The Problem

Over 80 million Americans use opioids for chronic pain (COPT), yet no approved therapy eliminates the risk of dependence.

The opioid crisis demands a novel solution targeting the root molecular cause — not just the symptoms.

## ATX-1209 (LD 6 $\beta$ N)

A novel, once-daily oral addiction modulator that binds to the mu opioid receptor (MOR), gradually reversing receptor adaptation — **suppressing dependence signals while fully preserving analgesic benefit.**

Chronic Pain (COPT)

Opioid Use Disorder

Neonatal OUD (NOWS)

## EVIDENCE PACKAGE

DOMAIN	STATUS
<b>Efficacy</b>	Consistent results across multiple nonclinical pain, dependence, drug-seeking & hyperalgesia models in multiple species; proof of mechanism demonstrated in opioid-treated patients
<b>Safety</b>	Clean two-species toxicology (oral formulation); human safety confirmed in prior Phase 1 at doses exceeding planned studies
<b>Stage</b>	Phase 1/2 clinical studies — clinical objective: reduced dependence in COPT patients without change in analgesic benefit

## INVESTMENT HIGHLIGHTS

**\$10M**

CURRENT RAISE

Convertible note · \$6M committed

**10X+**

RETURN POTENTIAL

Lilly/SiteOne, Latigo Series B (2025)

**< 3 Yrs**

EXIT TIMELINE

Early exit or continued value creation

## LEADERSHIP TEAM

NAME	ROLE	BACKGROUND
<b>Aaron Schuchart, MBA</b>	President & CEO	30 years; Amgen, Novartis, Coherus; C-suite at two public biotechs; multiple capital raises & strategic transactions
<b>Wolfgang Sadee, PhD</b>	Co-founder, CSO	Professor OSU/UCSF; >400 publications; top 0.05% cited scholar
<b>Bruce Imbert, MD, PhD</b>	CMO & Head of R&D	20+ years clinical development & regulatory; Indivior, TemperoBio, Pear Therapeutics; lead clinician for Sublocade & Opvee
<b>Laurence Nore, MBA</b>	Fractional COO	25+ years ops/BD leadership; Amgen, Roche
<b>Rick Hawkins</b>	Co-founder, Chairman	Founded & sold Pharmaco, Sensus, Covance, Lumos; 40-year biotech veteran

Product profile projected based on published non-clinical studies. Valuation benchmarks: Lilly/SiteOne; Latigo Biosciences Series B, 2025.

FOR INFORMATION PURPOSES ONLY • NOT A SOLICITATION